Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 479

1.

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation.

Karlsson H, Senkowski W, Fryknäs M, Mansoori S, Linder S, Gullbo J, Larsson R, Nygren P.

Oncotarget. 2019 Sep 3;10(51):5372-5382. doi: 10.18632/oncotarget.27166. eCollection 2019 Sep 3.

PMID:
31523395
2.

A smart friction control strategy enabled by CO2 absorption and desorption.

Hua J, Björling M, Grahn M, Larsson R, Shi Y.

Sci Rep. 2019 Sep 13;9(1):13262. doi: 10.1038/s41598-019-49864-w.

3.

Lost in Translation? Care Coordination Across Contexts in Swedish Homecare Nursing.

Erlingsdottir G, Persson J, Johansson G, Larsson R, Rydenfält C.

Stud Health Technol Inform. 2019 Aug 9;265:42-47. doi: 10.3233/SHTI190135.

PMID:
31431575
4.

Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity.

Niklasson M, Bergström T, Jarvius M, Sundström A, Nyberg F, Haglund C, Larsson R, Westermark B, Segerman B, Segerman A.

J Pathol. 2019 Jul 12. doi: 10.1002/path.5317. [Epub ahead of print]

PMID:
31298733
5.

High-density lipoproteins induce miR-223-3p biogenesis and export from myeloid cells: Role of scavenger receptor BI-mediated lipid transfer.

Cuesta Torres LF, Zhu W, Öhrling G, Larsson R, Patel M, Wiese CB, Rye KA, Vickers KC, Tabet F.

Atherosclerosis. 2019 Jul;286:20-29. doi: 10.1016/j.atherosclerosis.2019.04.227. Epub 2019 May 2.

PMID:
31096070
6.

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition.

Blom K, Rubin J, Berglund M, Jarvius M, Lenhammar L, Parrow V, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R.

BMC Res Notes. 2019 Apr 22;12(1):234. doi: 10.1186/s13104-019-4273-5.

7.

Drivers of changing urban flood risk: A framework for action.

Berndtsson R, Becker P, Persson A, Aspegren H, Haghighatafshar S, Jönsson K, Larsson R, Mobini S, Mottaghi M, Nilsson J, Nordström J, Pilesjö P, Scholz M, Sternudd C, Sörensen J, Tussupova K.

J Environ Manage. 2019 Jun 15;240:47-56. doi: 10.1016/j.jenvman.2019.03.094. Epub 2019 Mar 28.

PMID:
30928794
8.

Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling.

Jia TY, Xiong JF, Li XY, Yu W, Xu ZY, Cai XW, Ma JC, Ren YC, Larsson R, Zhang J, Zhao J, Fu XL.

Eur Radiol. 2019 Sep;29(9):4742-4750. doi: 10.1007/s00330-019-06024-y. Epub 2019 Feb 18.

PMID:
30778717
9.

Automatic Delineation of the Clinical Target Volume in Rectal Cancer for Radiation Therapy using Three-dimensional Fully Convolutional Neural Networks.

Larsson R, Xiong JF, Song Y, Ling-Fu, Chen YZ, Xiaowei X, Zhang P, Zhao J.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:5898-5901. doi: 10.1109/EMBC.2018.8513506.

PMID:
30441678
10.

Breast Region Segmentation being Convolutional Neural Network in Dynamic Contrast Enhanced MRI.

Xu X, Fu L, Chen Y, Larsson R, Zhang D, Suo S, Hua J, Zhao J.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:750-753. doi: 10.1109/EMBC.2018.8512422.

PMID:
30440504
11.

A 3D Convolutional Neural Network Framework for Polyp Candidates Detection on the Limited Dataset of CT Colonography.

Chen Y, Ren Y, Fu L, Xiong J, Larsson R, Xu X, Sun J, Zhao J.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:678-681. doi: 10.1109/EMBC.2018.8512305.

PMID:
30440487
12.

Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing.

Rubin J, Mansoori S, Blom K, Berglund M, Lenhammar L, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R.

Oncotarget. 2018 Jul 20;9(56):30805-30813. doi: 10.18632/oncotarget.25713. eCollection 2018 Jul 20.

13.

Population specific sperm production in European flounder Platichthys flesus: Adaptation to salinity at spawning.

Nissling A, Larsson R.

J Fish Biol. 2018 Jul;93(1):47-52. doi: 10.1111/jfb.13667.

PMID:
29882275
14.

Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors.

Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson R, Nygren P, Stålberg P.

Endocr Relat Cancer. 2018 Apr;25(4):471-480. doi: 10.1530/ERC-17-0404. Epub 2018 Feb 12.

PMID:
29440231
15.

Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.

Kashif M, Andersson C, Mansoori S, Larsson R, Nygren P, Gustafsson MG.

Oncotarget. 2017 Oct 19;8(61):103952-103967. doi: 10.18632/oncotarget.21895. eCollection 2017 Nov 28.

16.

Targeting tumor cells based on Phosphodiesterase 3A expression.

Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Fryknäs M.

Exp Cell Res. 2017 Dec 15;361(2):308-315. doi: 10.1016/j.yexcr.2017.10.032. Epub 2017 Oct 26.

PMID:
29107068
17.

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Eriksson A, Chantzi E, Fryknäs M, Gullbo J, Nygren P, Gustafsson M, Höglund M, Larsson R.

Leuk Res. 2017 Dec;63:41-46. doi: 10.1016/j.leukres.2017.10.012. Epub 2017 Oct 28.

18.

Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J.

Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12. Review.

19.

In Vitro and In Vivo Biocompatibility Evaluation of Polyallylamine and Macromolecular Heparin Conjugates Modified Alginate Microbeads.

Vaithilingam V, Steinkjer B, Ryan L, Larsson R, Tuch BE, Oberholzer J, Rokstad AM.

Sci Rep. 2017 Sep 15;7(1):11695. doi: 10.1038/s41598-017-11989-1.

20.

Mass spectrometry based metabolomics for in vitro systems pharmacology: pitfalls, challenges, and computational solutions.

Herman S, Emami Khoonsari P, Aftab O, Krishnan S, Strömbom E, Larsson R, Hammerling U, Spjuth O, Kultima K, Gustafsson M.

Metabolomics. 2017;13(7):79. doi: 10.1007/s11306-017-1213-z. Epub 2017 May 19.

21.

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation.

Blom K, Senkowski W, Jarvius M, Berglund M, Rubin J, Lenhammar L, Parrow V, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R.

Immunopharmacol Immunotoxicol. 2017 Aug;39(4):199-210. doi: 10.1080/08923973.2017.1320671. Epub 2017 May 4.

PMID:
28472897
22.

Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin.

Jiang Y, Marinescu VD, Xie Y, Jarvius M, Maturi NP, Haglund C, Olofsson S, Lindberg N, Olofsson T, Leijonmarck C, Hesselager G, Alafuzoff I, Fryknäs M, Larsson R, Nelander S, Uhrbom L.

Cell Rep. 2017 May 2;19(5):1080-1081. doi: 10.1016/j.celrep.2017.04.053. No abstract available.

23.

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.

Karlsson H, Fryknäs M, Strese S, Gullbo J, Westman G, Bremberg U, Sjöblom T, Pandzic T, Larsson R, Nygren P.

Oncotarget. 2017 May 2;8(18):30217-30234. doi: 10.18632/oncotarget.16324.

24.

Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis.

Blom K, Nygren P, Larsson R, Andersson CR.

SLAS Technol. 2017 Jun;22(3):306-314. doi: 10.1177/2472630316686297. Epub 2017 Jan 31.

PMID:
28378608
25.

Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin.

Jiang Y, Marinescu VD, Xie Y, Jarvius M, Maturi NP, Haglund C, Olofsson S, Lindberg N, Olofsson T, Leijonmarck C, Hesselager G, Alafuzoff I, Fryknäs M, Larsson R, Nelander S, Uhrbom L.

Cell Rep. 2017 Jan 24;18(4):977-990. doi: 10.1016/j.celrep.2017.01.003. Erratum in: Cell Rep. 2017 May 2;19(5):1080-1081.

26.

Mouse Models of Pediatric Supratentorial High-grade Glioma Reveal How Cell-of-Origin Influences Tumor Development and Phenotype.

Sreedharan S, Maturi NP, Xie Y, Sundström A, Jarvius M, Libard S, Alafuzoff I, Weishaupt H, Fryknäs M, Larsson R, Swartling FJ, Uhrbom L.

Cancer Res. 2017 Feb 1;77(3):802-812. doi: 10.1158/0008-5472.CAN-16-2482. Epub 2016 Nov 15.

27.

Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB).

De Rosa M, Lu L, Zamaratski E, Szałaj N, Cao S, Wadensten H, Lenhammar L, Gising J, Roos AK, Huseby DL, Larsson R, Andrén PE, Hughes D, Brandt P, Mowbray SL, Karlén A.

Bioorg Med Chem. 2017 Feb 1;25(3):897-911. doi: 10.1016/j.bmc.2016.12.003. Epub 2016 Dec 7.

28.

Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids.

Senkowski W, Jarvius M, Rubin J, Lengqvist J, Gustafsson MG, Nygren P, Kultima K, Larsson R, Fryknäs M.

Cell Chem Biol. 2016 Nov 17;23(11):1428-1438. doi: 10.1016/j.chembiol.2016.09.013. Epub 2016 Oct 27.

29.

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.

Strese S, Hassan SB, Velander E, Haglund C, Höglund M, Larsson R, Gullbo J.

Oncotarget. 2017 Jan 24;8(4):6341-6352. doi: 10.18632/oncotarget.13856.

30.

Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition.

Segerman A, Niklasson M, Haglund C, Bergström T, Jarvius M, Xie Y, Westermark A, Sönmez D, Hermansson A, Kastemar M, Naimaie-Ali Z, Nyberg F, Berglund M, Sundström M, Hesselager G, Uhrbom L, Gustafsson M, Larsson R, Fryknäs M, Segerman B, Westermark B.

Cell Rep. 2016 Dec 13;17(11):2994-3009. doi: 10.1016/j.celrep.2016.11.056.

31.

Iron chelators target both proliferating and quiescent cancer cells.

Fryknäs M, Zhang X, Bremberg U, Senkowski W, Olofsson MH, Brandt P, Persson I, D'Arcy P, Gullbo J, Nygren P, Schughart LK, Linder S, Larsson R.

Sci Rep. 2016 Dec 7;6:38343. doi: 10.1038/srep38343.

32.

Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.

Österroos A, Kashif M, Haglund C, Blom K, Höglund M, Andersson C, Gustafsson MG, Eriksson A, Larsson R.

Biochem Pharmacol. 2016 Oct 15;118:40-49. doi: 10.1016/j.bcp.2016.08.020. Epub 2016 Aug 24.

PMID:
27565890
33.

Preclinical activity of melflufen (J1) in ovarian cancer.

Carlier C, Strese S, Viktorsson K, Velander E, Nygren P, Uustalu M, Juntti T, Lewensohn R, Larsson R, Spira J, De Vlieghere E, Ceelen WP, Gullbo J.

Oncotarget. 2016 Sep 13;7(37):59322-59335. doi: 10.18632/oncotarget.11163.

34.

A stochastic two-scale model for pressure-driven flow between rough surfaces.

Pérez-Ràfols F, Larsson R, Lundström S, Wall P, Almqvist A.

Proc Math Phys Eng Sci. 2016 Jun;472(2190):20160069.

35.

In vitro and in vivo activity of melflufen (J1)in lymphoma.

Delforoush M, Strese S, Wickström M, Larsson R, Enblad G, Gullbo J.

BMC Cancer. 2016 Apr 4;16:263. doi: 10.1186/s12885-016-2299-9.

36.

Managing workplace health promotion in municipal organizations: The perspective of senior managers.

Larsson R, Åkerlind I, Sandmark H.

Work. 2015;53(3):485-98. doi: 10.3233/WOR-152177.

PMID:
26519015
37.

Serotonergic medication enhances the association between suicide and sunshine.

Makris GD, Reutfors J, Larsson R, Isacsson G, Ösby U, Ekbom A, Ekselius L, Papadopoulos FC.

J Affect Disord. 2016 Jan 1;189:276-81. doi: 10.1016/j.jad.2015.09.056. Epub 2015 Oct 8.

PMID:
26454332
38.

In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index.

Kashif M, Andersson C, Hassan S, Karlsson H, Senkowski W, Fryknäs M, Nygren P, Larsson R, Gustafsson MG.

Sci Rep. 2015 Sep 22;5:14118. doi: 10.1038/srep14118.

39.

Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy.

Blom K, Nygren P, Alvarsson J, Larsson R, Andersson CR.

J Lab Autom. 2016 Feb;21(1):178-87. doi: 10.1177/2211068215598117. Epub 2015 Aug 5.

PMID:
26246423
40.

Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.

Bjersand K, Mahteme H, Sundström Poromaa I, Andréasson H, Graf W, Larsson R, Nygren P.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S810-6. doi: 10.1245/s10434-015-4675-0. Epub 2015 Jul 21.

41.

Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer.

Senkowski W, Zhang X, Olofsson MH, Isacson R, Höglund U, Gustafsson M, Nygren P, Linder S, Larsson R, Fryknäs M.

Mol Cancer Ther. 2015 Jun;14(6):1504-16. doi: 10.1158/1535-7163.MCT-14-0792. Epub 2015 Apr 24.

42.

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia.

Eriksson A, Österroos A, Hassan S, Gullbo J, Rickardson L, Jarvius M, Nygren P, Fryknäs M, Höglund M, Larsson R.

Blood Cancer J. 2015 Apr 17;5:e307. doi: 10.1038/bcj.2015.31.

43.

Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation.

Nordling S, Hong J, Fromell K, Edin F, Brännström J, Larsson R, Nilsson B, Magnusson PU.

Thromb Haemost. 2015 Jun;113(6):1312-22. doi: 10.1160/TH14-09-0724. Epub 2015 Mar 5.

PMID:
25740465
44.

DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia.

Nordlund J, Bäcklin CL, Zachariadis V, Cavelier L, Dahlberg J, Öfverholm I, Barbany G, Nordgren A, Övernäs E, Abrahamsson J, Flaegstad T, Heyman MM, Jónsson ÓG, Kanerva J, Larsson R, Palle J, Schmiegelow K, Gustafsson MG, Lönnerholm G, Forestier E, Syvänen AC.

Clin Epigenetics. 2015 Feb 17;7:11. doi: 10.1186/s13148-014-0039-z. eCollection 2015.

45.
46.

Rate sensitive continuum damage models and mesh dependence in finite element analyses.

Ljustina G, Fagerström M, Larsson R.

ScientificWorldJournal. 2014;2014:260571. doi: 10.1155/2014/260571. Epub 2014 Nov 3.

47.

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy.

Hultman B, Mahteme H, Sundbom M, Ljungman M, Larsson R, Nygren P.

J Exp Clin Cancer Res. 2014 Dec 21;33:110. doi: 10.1186/s13046-014-0110-9.

48.

Detection of cell aggregation and altered cell viability by automated label-free video microscopy: a promising alternative to endpoint viability assays in high-throughput screening.

Aftab O, Fryknäs M, Hammerling U, Larsson R, Gustafsson MG.

J Biomol Screen. 2015 Mar;20(3):372-81. doi: 10.1177/1087057114562158. Epub 2014 Dec 17.

PMID:
25520371
49.

The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.

Lindqvist CM, Nordlund J, Ekman D, Johansson A, Moghadam BT, Raine A, Övernäs E, Dahlberg J, Wahlberg P, Henriksson N, Abrahamsson J, Frost BM, Grandér D, Heyman M, Larsson R, Palle J, Söderhäll S, Forestier E, Lönnerholm G, Syvänen AC, Berglund EC.

Hum Mutat. 2015 Jan;36(1):118-28. doi: 10.1002/humu.22719.

50.

Evolution of a morphological novelty occurred before genome compaction in a lineage of extreme parasites.

Haag KL, James TY, Pombert JF, Larsson R, Schaer TM, Refardt D, Ebert D.

Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15480-5. doi: 10.1073/pnas.1410442111. Epub 2014 Oct 13. Erratum in: Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1162.

Supplemental Content

Loading ...
Support Center